Varanasi News Magazine

Sarcopenia Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

 Breaking News
  • No posts were found

Sarcopenia Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

November 14
22:49 2022
Sarcopenia Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market
DelveInsight Business Research LLP
DelveInsight’s “Sarcopenia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Sarcopenia, historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s “Sarcopenia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Sarcopenia, historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Sarcopenia market report provides current treatment practices, emerging drugs, Sarcopenia market share of individual therapies, and current and forecasted Sarcopenia market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Sarcopenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Sarcopenia market.

Some of the key facts of the Sarcopenia Market Report:

  • In one of the studies titled “Prevalence and risk factors of sarcopenia in community-dwelling older adults visiting regional medical institutions from the Kadoma Sarcopenia Study”, conducted by Kurose et. al. (2020), Sarcopenia, including severe sarcopenia, was detected in 22.3% of all participants

  • In a study conducted by Yamaguchi et. al. (2020) on elderly patients with diabetes from Japan and Taiwan, Sarcopenia was found in 10.6% in Japan and 11.1% in Taiwan

  • In the study conducted by Chang et. al. (2020), Sarcopenia prevalence, determined using the AWGS-recommended algorithm, was 40.3% and 41.3% in men and women, respectively. The overall prevalence of sarcopenia was 41.0% by the AWGS-recommended algorithm.

Key Benefits of the Sarcopenia Market Report:

  • The report covers the descriptive overview of Sarcopenia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

  • Comprehensive insight has been provided into the Sarcopenia epidemiology and treatment in the 7MM

  • Additionally, an all-inclusive account of both the current and emerging therapies for Sarcopenia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

  • A detailed review of the Sarcopenia market; historical and forecasted is included in the report, covering drug outreach in the 7MM

  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Sarcopenia market

 

Got queries? Click here to learn more about the Sarcopenia Market Landscape

Sarcopenia Overview

Sarcopenia is a condition that is characterized by loss of muscle mass, muscle strength, and functional muscle impairment with aging. The definition has been through various alterations. However, an enormous recent breakthrough is the inclusion of the condition in the ICD-10 classification of diseases. The physical consequences of this disease put a person at risk for falls, fractures, and hospitalization, thereby affecting the quality of life and death in extreme cases.

There are currently no approved drug treatments for sarcopenia. The condition requires a multimodal management approach combining a nutritional strategy targeting nutrient quality and intake, exercise, and anti-inflammatory and anabolic medications. Treatments have focused mostly on extrinsic approaches such as exercise and diet, but recent scientific advances have brought greater attention to additional treatment options.

 

Sarcopenia Epidemiological Insights:

 

  • The prevalence of sarcopenia depends on the definition applied and the attributes of the target population. Current definitions of sarcopenia are only newly developed and still not entirely accepted. Reported prevalence rates of sarcopenia vary significantly due to differing definitions, tools of diagnosis, and patient populations. Estimates range from 10% in individuals >65 years of age, rising to 30% in men over 80.

 

  • In a study conducted by Kitamura et. al. (2020) on Japanese residents of the age group 65 years and above, the prevalence of sarcopenia was approximately 14%. Overall, 11.5% of men and 16.7% of women were affected by the disease in Japan.

 

  • A study conducted in 2019 titled “Sarcopenia Prevalence and Risk Factors among Japanese Community-dwelling Older Adults Living in a Snow-Covered City According to EWGSOP2,” by Ya Su et al., quoted that in Japan, the prevalence of sarcopenia among community-dwelling older adults aged 65–89 years was 21.8% in men and 22.1% in women.

 

  • Ya Su et al. (2019) mentioned in their study that According to the EWGSOP2, sarcopenia has a low prevalence (8.1%) in Japanese community-dwelling older adults living in snow-covered cities of Japan. The prevalence rates of sarcopenia among men and women are 10.1% and 7.2%, respectively. 

 

Sarcopenia Epidemiological Segmentation 

  • Total Sarcopenia prevalent cases 

  • Total Sarcopenia gender specific prevelant cases 

  • Total Sarcopenia diagnosed cases 

  • Total Sarcopenia treatable cases 

Sarcopenia Market Outlook 

The Sarcopenia market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Sarcopenia market trends by analyzing the impact of current Sarcopenia therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

;

This segment gives a thorough detail of the Sarcopenia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Sarcopenia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Sarcopenia market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Learn more by requesting for sample @ Sarcopenia Market Trends

Sarcopenia Key Companies

  • Mesoblast/ Gruenthal

  • Stayble Therapeutics

  • Kuros Biosciences

  • And many more

 

Sarcopenia Therapies

 

  • Rexlemestrocel

  • STA363

  • Fibrin-PTH (KUR-113)

  • IDCT (rebonuputemcel) 

  • And many others

 

Table of Contents

 

  1. Key Insights 

  2. Report Introduction 

  3. Executive Summary of CSarcopenia     

  4. Disease Background and Overview

  5. Epidemiology and patient population

  6. Sarcopenia Emerging Therapies

  7. Sarcopenia Market Outlook

  8. Market Access and Reimbursement of Therapies

  9. Appendix

  10. Sarcopenia   Report Methodology

  11. DelveInsight Capabilities

  12. Disclaimer

  13. About DelveInsight

Click here to read more about  Sarcopenia Market Insight

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/